Reactivación de la hepatitis B tratada con adefovir tras la administración de infliximab

Núñez-Rodríguez, María Henar; Santamaría-Martínez, Ana; Mata-Román, Laura; Caro-Patón, A.

doi:10.1157/13087150

Cited by 9 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, more data are available in literature for patients with chronic HBV infection (HBsAg positive). In total, 103 patients HBsAg positive with concomitant psoriasis and IT have been described in literature [ 20 , 24 , 25 , 34 , 35 ]; 56/103 of these patients were treated with concomitant antiviral therapy and only 5/56 (8.9%) showed HBV reactivation [ 35 ]. Differently, among the remaining patients without antiviral prophylaxis, 32/47 (68%) patients showed HBV reactivation during biological therapy [ 25 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis

et al. 2014

View full text Add to dashboard Cite

BackgroundHBV and HCV reactivation have been widely reported in patients undergoing immunosuppressive therapy (IT); however, few data are available on the risk of reactivation in patients with psoriasis receiving IT. The aim of our study was to assess the prevalence of HBV and HCV infection in patients with psoriasis and to evaluate the effects of IT during the course of the infection.MethodsThe study included psoriatic patients who attended an Italian tertiary referral hospital from 2009 to 2012. A total of 224 patients were enrolled. We evaluated: HBV and HCV markers, type of IT and the occurrence of viral reactivation. The observational period ranged from the beginning of IT to the last visit, with a mean follow-up period of 54 months.ResultsTwo hundred and twenty patients (135 males and 89 females; mean age 59 years; range 18–86 years) with psoriasis, with or without psoriatic arthritis, receiving conventional IT and/or biological drugs were tested for markers of infection. We identified 23/224 patients (10.2%) with isolated positivity for HBcAb positivity, 36/224 (16%) with positivity for HBsAb/HBcAb, and 15/224 (6.6%) with positivity for HCV-Ab. No patient was HBsAg positive, none of them underwent pre-emptive therapy with lamivudine or other antiviral drugs and no one showed episodes of viral reactivation.ConclusionsThe prevalence of HBsAg in patients with psoriasis is lower than that observed in the general population. The prevalence of isolated positivity for HBcAb and of combined positivity for HBcAb and HBsAb is 10.2% and 16%, respectively. The prevalence of HCV infection (HCV-RNA+) is 4%. In patients with psoriasis and HCV-Ab or HBcAb positivity, the IT seems to be safe, regardless of the type of drugs.

show abstract

Section: Discussionmentioning

confidence: 99%

Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis

et al. 2014

View full text Add to dashboard Cite

show abstract

Targeted Treatments for Inflammatory Bowel Diseases

MacCarthy

Egan

2010

Inflammatory Bowel Disease

View full text Add to dashboard Cite

Current awareness: Pharmacoepidemiology and drug safety

2006

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Reactivación de la hepatitis B tratada con adefovir tras la administración de infliximab

Cited by 9 publications

References 4 publications

Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis

Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis

Targeted Treatments for Inflammatory Bowel Diseases

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About